TMDX241220C22500
- 22.50
- 0.000.00%
TransMedics Newsroom
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Maintains Target Price $80
Morgan Stanley Maintains TransMedics(TMDX.US) With Hold Rating, Cuts Target Price to $80
TransMedics Group: Balancing Long-term Promise With Short-term Uncertainty – Hold Rating Maintained
Piper Sandler Maintains TransMedics(TMDX.US) With Buy Rating, Cuts Target Price to $90
Oppenheimer Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $125
TransMedics Group Is Maintained at Overweight by Piper Sandler
A Quick Look at Today's Ratings for TransMedics(TMDX.US), With a Forecast Between $90 to $120
TransMedics Group (TMDX) Gets a Buy From Oppenheimer
Express News | Baird Maintains Outperform on TransMedics Gr, Lowers Price Target to $120
Beyond The Numbers: 13 Analysts Discuss TransMedics Gr Stock
TransMedics Price Target Lowered to $90 From $110 at Piper Sandler
Needham Reiterates Hold on TransMedics Grto Hold
TransMedics Gr Analyst Ratings
Express News | Transmedics Group Inc : Piper Sandler Cuts Target Price to $90 From $110
TransMedics Group: Promising Growth Trajectory With Strategic Expansion and Clinical Advancements
$1000 Invested In TransMedics Gr 5 Years Ago Would Be Worth This Much Today
TransMedics Sees FY25 Revenue Growth 20%-25% Over Midpoint of FY24 Guide
CCORF Maintains TransMedics(TMDX.US) With Buy Rating, Maintains Target Price $104
Positive Outlook for TransMedics Group Amid DCD Market Growth and Transplant Volume Variability
TransMedics Group, Inc. (TMDX): A Bull Case Theory